MedTrace Logo

Nephrogenic Systemic Fibrosis With Gadollinum

NCT01359345 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2012-06-22

No results posted yet for this study

Summary

Recently there is increasing reports of NEPHROGENIIC SYSTEMIC FIBROSIS(NSF) in patients with severe renal failure mainly in patients under dialysis in whom gadollinum is being used.

The investigators will evaluate the prevalence and severity of NSF in patients with different degree of renal failure whom underwent imaging with Gadolinum.

Conditions

  • Nephrogenic Systemic Fibrosis
  • Renal Failure

Interventions

DRUG

gadollinum

use of on injection gadollinum Iv for imaging

Sponsors & Collaborators

  • Tehran Heart Center

    collaborator OTHER

  • Imam Khomeini Hospital

    lead OTHER

Principal Investigators

  • Mohammad R Khatami, MD · TUMS

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2011-05-31
Completion
2012-08-31

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01359345 on ClinicalTrials.gov